Mouhannad Azzouz, MD
Neurology · Morgantown, WVNPI 1760506018
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,575 of the $40,253 with a category attached, or 63.5%. Axsome Therapeutics, Inc. accounts for 69.7% of it on its own, with 42 other manufacturers making up the rest. 2025 is the largest year on record at $26,715, more than ten times the $1,111 reported in 2019. Among neurology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 681 payments — averaging $59.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$28K
- Jazz Pharmaceuticals Inc.$2K
- Harmony Biosciences LLC$2K
- AbbVie$864
- Pfizer$715
- UCB, Inc.$682
- plus $6K from 37 others
Across 4 payments — averaging $7156.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Harmony Biosciences LLC$29K
What the payments were for
- Consulting fees$2,3006%
- Speaking & faculty fees$25,57564%
- Food & beverage$11,66629%
- Education$7122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,253 in reported general payments places this provider in the 90th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 17 | $207,135 |
| AustedoDeutetrabenazine | 13 | $188,435 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $105,732 |
| CopaxoneGlatiramer Acetate | 14 | $80,727 |
| AmpyraDalfampridine | 13 | $55,370 |
| SunosiSolriamfetol Hcl | 34 | $37,743 |
| AptiomEslicarbazepine Acetate | 13 | $25,785 |
| VimpatLacosamide | 15 | $17,745 |
| Oxtellar XrOxcarbazepine | 15 | $17,364 |
| BelsomraSuvorexant | 27 | $12,427 |
| Lamotrigine ErLamotrigine | 14 | $9,871 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,904 |
| Lacosamide | 29 | $2,680 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 61 | $2,493 |
| Modafinil | 60 | $2,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $541 | $269,16127 claims |
| Harmony Biosciences LLCWakix | $1,666 | $207,13517 claims |
| BiogenAvonex (4 Pack) | $78 | $105,73213 claims |
| Axsome Therapeutics, Inc.Sunosi | $28,051 | $37,74334 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $382 | $25,78513 claims |
| UCB, Inc.Vimpat | $682 | $17,74515 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $237 | $17,36415 claims |
| Upsher-smith Laboratories LLCTopiramate | $92 | $24230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 neurology providers in West Virginia.
Other neurology in Morgantown
- Umer NajibMorgantown$246K
- Cheryl SmithMorgantown$68K
- Maria Moreno EscobarMorgantown$23K
- Shumaila SultanMorgantown$13K
- Ann MurrayMorgantown$12K
- Violina MelnicMorgantown$12K
- Melanie WardMorgantown$9K
- Richa TripathiMorgantown$8K
- Phong VuMorgantown$5K
- Ruchi DhyaniMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.